Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Efonidipine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C known ✓ | Q13936 | 8/20 | 0.58 |
| ▸ | ADRA2A known ✓ | P08913 | 3/20 | 0.58 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.58 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.58 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.58 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.58 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.58 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.58 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.58 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.58 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.58 |
| ▸ | DRD3 known ✓ | P35462 | 1/20 | 0.58 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.58 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.58 |
| ▸ | SCN5A known ✓ | Q14524 | 1/20 | 0.58 |
| ▸ | CACNA1F known ✓ | O60840 | 7/20 | 0.51 |
| ▸ | CACNA1D known ✓ | Q01668 | 7/20 | 0.51 |
| ▸ | CACNA1S known ✓ | Q13698 | 7/20 | 0.51 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C known ✓ | P18825 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efonidipine SCHEMBL349046 | 1.00 | ABCB1 (0.99) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL29410289 | 0.99 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL49637 | 0.99 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL49638 | 0.99 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL29379054 | 0.99 | ABCB1 (1.00) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL909287 | 0.98 | ABCB1 (0.95) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL909286 | 0.98 | ABCB1 (0.95) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL678571 | 0.98 | ABCB1 (0.97) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL28844127 | 0.98 | ABCB1 (0.97) | ABCB1LMNACYP1A2CYP3A4CYP2D6 | |
| Efonidipine SCHEMBL27650540 | 0.97 | ABCB1 (0.96) | ABCB1LMNACYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 608 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| CN-111405895-B | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2022-10-21 | — | — | CN | claimed |
| CN-112409412-A | Improved synthesis process of antihypertensive efonidipine hydrochloride | 重庆化工职业学院 | 2021-02-26 | — | — | CN | claimed |
| CN-111405895-A | Controlled release pharmaceutical composition and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2020-07-10 | — | — | CN | claimed |
| WO-2016130385-A2 | TISSUE ABLATION BY RAPID AND SUSTAINED ALTERATION IN MEMBRANE POTENTIAL | EKEMA GEORGE MBELLA (US) | 2016-08-18 | — | — | WO | claimed |
| CN-102512400-B | Preparation method of efonidipine hydrochloride tablet | SHENZHEN MAIN LUCK PHARMACEUTICALS INC | 2014-04-16 | — | — | CN | claimed |
| US-7807701-B2 | Dibenzylamine compounds and pharmaceutical use thereof | JAPAN TOBACCO INC. (JP) | 2010-10-05 | — | — | US | claimed |
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. | 2010-06-24 | — | — | US | claimed |
| US-7625948-B2 | Ester compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2009-12-01 | — | — | US | claimed |
| WO-2002009761-A9 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORP (US) | 2003-07-10 | — | — | WO | claimed |
| EP-1303305-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | Pharmacia Corporation (US) | 2003-04-23 | — | — | EP | claimed |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | G. D. SEARLE & CO. (US) | 2003-03-20 | — | — | US | claimed |
| EP-0893999-B8 | PROCESS FOR PRODUCING EFONIDIPINE HYDROCHLORIDE PREPARATIONS | NISSAN CHEMICAL IND LTD (JP) | 2003-01-02 | — | — | EP | claimed |
| EP-0893999-B1 | PROCESS FOR PRODUCING EFONIDIPINE HYDROCHLORIDE PREPARATIONS | NISSAN CHEMICAL IND LTD (JP) | 2002-09-11 | — | — | EP | claimed |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | SCHUH JOSEPH R (US) | 2002-04-11 | — | — | US | claimed |
| WO-2002009761-A2 | EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND CALCIUM CHANNEL BLOCKER COMBINATION THERAPY FOR TREATMENT OF CONGESTIVE HEART FAILURE | PHARMACIA CORPORATION (US) | 2002-02-07 | — | — | WO | claimed |
| US-6171599-B1 | HEAT TREATMENT; DIPPING AND IMPREGNATING WITH WATER CONTAINING SOLUTION; STEAMING; HYPOTENSIVE AGENTS; HIGH INTESTINAL ABSORBABILITY | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| EP-0893999-A1 | PROCESS FOR PRODUCING EFONIDIPINE HYDROCHLORIDE PREPARATIONS | NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) | 1999-02-03 | — | — | EP | claimed |
| WO-1997034610-A1 | PROCESS FOR PRODUCING EFONIDIPINE HYDROCHLORIDE PREPARATIONS | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 1997-09-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100158996-A1 | ESTER COMPOUND AND MEDICAL USE THEREOF | LIPC, CES1, MTTP | CACNA1C 3698/4885ADRA2A 2511/4885CHRM2 440/4885 |
| US-20030055027-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | PTGER1, KCNN4, HCN1 | CACNA1C 9/4885ADRA2A 225/4885CHRM2 467/4885 |
| US-20020042405-A1 | Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure | KCNN4, NR3C2, EDNRA | CACNA1C 5/4885ADRA2A 98/4885CHRM2 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.